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Abstract: Adult-onset Still’s disease (AOSD) is a rare inflammatory disorder that has been 
recently classified as a polygenic autoinflammatory disorder. The former classification, based on 
the disease course, seems to be quite dated. Indeed, there is accumulating evidence that AOSD 
can be divided into two distinct phenotypes based on cytokine profile, clinical presentation, and 
outcome, ie, a “systemic” pattern and an “articular” pattern. The first part of this review deals 
with the treatments that are currently available for AOSD. We then present the different strate-
gies based on the characteristics of the disease according to clinical presentation. To do so, we 
focus on the two subsets of the disease. Finally, we discuss the management of life-threatening 
complications of AOSD, along with the therapeutic options during pregnancy.
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Introduction
Adult-onset Still’s disease (AOSD) is a rare inflammatory disorder characterized by the 
classical triad of daily spiking fever, arthritis, and typical salmon-colored rash. It was 
first described in 1971 by Bywaters, who defined the disease on the basis of clinical and 
laboratory resemblance to juvenile Still’s disease.1 Indeed, in 1897, George Frederic 
Still had described 22 children with what is now called systemic-onset idiopathic 
juvenile arthritis (JIA).2,3 Whether AOSD and systemic-onset JIA belong to the same 
continuum of disease is still debated, but the evidence strongly suggests that AOSD 
and systemic-onset JIA are the same disease.4–6
The epidemiology, diagnostic criteria7,8 (Table 1), and classification of AOSD 
have been reviewed recently.9,10 The pathophysiology of AOSD remains obscure, and 
identification of an etiologic trigger is still lacking.
Over the last decade, one striking event was the reclassification of AOSD as a poly-
genic autoinflammatory disorder.11,12 This has mainly been deduced from demonstration 
of the pivotal role of innate immune pathways, mostly those involved in the processing 
of two cytokines of the interleukin (IL)-1 family (namely, IL-1β and IL-18). Other 
cytokines, such as IL-6 and to a lesser extent tumor necrosis factor alpha (TNF-α), 
are also involved in the pathogenesis of AOSD. Data from genetic and immunologic 
studies, together with the dramatic effect of biologic treatments, have confirmed the 
major role of these cytokines. Recently, there has been accumulating evidence that 
AOSD can be divided into two distinct phenotypes based on cytokine profile, clinical 
presentation, and outcome.10,13–15 These are discussed in this review.
The renewed comprehension of the disease, along with the availability of new 
cytokine inhibitors, has led to new therapeutic approaches. The general aim of this 
review is to discuss the optimal management of AOSD. The first part deals with the 
treatments that are currently available for AOSD. We then present the different strate-
gies based on characteristics of the disease according to clinical presentation.
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Available treatments
Given that the current information on treatment efficacy is 
obtained from small retrospective case series and not from 
prospective, double-blind, randomized trials, the treatment 
of AOSD remains empirical. In contrast, due to a higher 
prevalence, more data are available for systemic-onset JIA 
and will be discussed briefly. Recently, the management of 
AOSD has benefited from proofs of the efficacy of targeted 
biotherapies.
Nonsteroidal anti-inflammatory drugs 
and corticosteroids 
Regarding available data on AOSD, the risk/benefit ratio is 
not favorable with regard to nonsteroidal anti-inflammatory 
drugs (NSAIDs). Indeed, more than 80% of AOSD patients 
did not achieve remission with NSAIDs and approximately 
20% suffered adverse events.16,17 Nevertheless, temporary 
use of NSAIDs can be considered during diagnostic workup 
or for early relapse of the disease.17
Corticosteroids remain the first-line treatment for 
AOSD, regardless of the clinical presentation. Nevertheless, 
studies of systemic-onset JIA are providing evidence that 
some biologics should be used earlier in the course of the 
disease (see section on IL-1 antagonists).18–21 In addition, 
new treatment plans for systemic-onset JIA have placed 
methotrexate, anakinra, and tocilizumab as possible first-
line treatments.22 Corticosteroids control about 60% of 
patients and show greater efficacy with regard to systemic 
symptoms than articular ones.17,23,24 Steroid dependency 
occurs in approximately 45% of cases. and has been asso-
ciated with splenomegaly, low glycosylated ferritin, an 
elevated erythrocyte sedimentation rate, and young age 
at onset of AOSD.16,25 Thus, early addition of a steroid-
sparing agent may be considered in patients who meet 
these criteria. 
Disease-modifying antirheumatic drugs 
and intravenous immunoglobulin 
In the event of failure of corticosteroid treatment or steroid-
dependence, disease-modifying anti-rheumatic drugs 
(DMARDS) can be considered.16,25 Some retrospective 
case series and case reports have reported the efficacy of 
several DMARDs, such as cyclosporine A, leflunomide, 
azathioprine, hydroxychloroquine,23,26 D-penicillamine, 
and tacrolimus.17,27,28 However, positive results remain 
exceptional and these agents cannot be recommended unless 
severe complications occur and other more specific drugs 
have failed.27
In contrast, methotrexate has proved beneficial 
and remains the first-line steroid-sparing treatment in 
AOSD.16,17 As for systemic-onset JIA, targeted biologic 
thera pies (such as anakinra or tocilizumab) are possible 
alternatives, which could be used for a steroid-sparing 
effect. Methotrexate can lead to complete remission in 
up to 70% of patients and corticosteroid weaning has also 
been reported in some cases.29 Liver enzyme abnormali-
ties do not contraindicate its prescription but require close 
biological monitoring.
Data concerning intravenous immunoglobulin are more 
controversial, with two randomized open-label trials showing 
some efficacy when used early in the course of AOSD,30,31 
whereas retrospective data do not support the efficacy of 
intravenous immunoglobulin in AOSD.16,25 Overall, intra-
venous immunoglobulin has only a suspensive effect but is 
well tolerated. Thus, it should be considered in the event of 
reactive hemophagocytic lymphohistiocytosis (RHL; for-
merly known as macrophage activation syndrome),32 in some 
life-threatening complications, or in case of AOSD flare-up 
occurring during pregnancy.33,34 The usual dosage is 2 g/kg 
body weight administered in 2–5 days.
Targeted biologic therapies
Although dramatic responses have been reported in systemic-
onset JIA when given as first-line treatment, targeted biologic 
agents are actually reserved for refractory AOSD.19,21,22,35 
Resistance to first-line corticosteroids and second-line 
DMARDs defines refractory AOSD, which mostly 
includes the polycyclic or chronic courses of the disease. 
Table 1 Criteria for the diagnosis of adult-onset Still’s disease
Major criteria Fever 39°C lasting 1 week
Arthralgia or arthritis lasting 2 weeks
Typical nonpruritic salmon-colored rash
 Leukocytosis 10,000/mm3 with 
granulocytes 80%
Minor criteria Sore throat
Lymphadenopathy
Splenomegaly
Abnormal liver function tests
Negative tests for antinuclear antibody 
and rheumatoid factor
exclusion criteria infection
Malignancy
 Other rheumatic disease (vasculitis)
Notes: Diagnosis of adult-onset Still’s disease if 5 criteria are present with 2 
being major criteria and no exclusion criteria. Data from.7
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Data concerning biologic agents used in AOSD are sum-
marized in Table 2.
Anti-TNF-α
Historically, anti-TNF therapy was the first biologic therapy 
that was used to treat refractory AOSD. The administra-
tion schemes were based on those used in the treatment 
of rheumatoid arthritis. The three anti-TNF-α agents (ie, 
infliximab, etanercept, and adalimumab) have been used to 
treat refractory AOSD but data on adalimumab are limited 
to a few cases.36 Data from case reports, retrospective case 
series, and one prospective open-label prospective trial are 
available. Complete remissions have been observed37–41 but 
anti-TNF therapy was rather disappointing, mostly for sys-
temic symptoms.10,42 Switching from one molecule to another 
had no additional effect.16,43 Moreover, two patients who were 
started on etanercept and adalimumab developed RHL that 
could be linked with initiation of the treatment.44,45 Overall, 
TNF-α blockers seem to be of interest only for the treatment 
of chronic polyarticular disease.16,17,23,25 In that case, based on 
our experience and on analysis of the literature, infliximab 
should be the preferred molecule because of better efficacy. 
However, no prospective evidence sustains this preferred 
option, and each case should be carefully evaluated by AOSD 
experts before therapeutic changes.
iL-1 antagonists
Three IL-1 antagonists are presently available, ie, a recom-
binant antagonist of the IL-1 receptor (IL-1Ra, anakinra), 
a human monoclonal antibody directed against IL-1β 
(canakinumab), and a soluble IL-1 trap fusion protein 
(rilonacept). Anakinra has been more frequently reported in 
the treatment of AOSD.35,46–52 
The efficacy of anakinra has been reported in retrospec-
tive case series35,46–51 and in one prospective, randomized, 
open-label trial.52 Anakinra is particularly efficient in the 
rapid relief of systemic symptoms. Its effect on articular 
symptoms is less frequently reported. In almost all cases, 
inflammatory markers reverted to normal within about 
2 weeks and corticosteroids could be tapered and discon-
tinued. However, the effect of anakinra was suspensive, 
and relapses occurred frequently as soon as the treatment 
was stopped. In some cases, progressive dose reduction has 
enabled the weaning of anakinra. In the event of an insuf-
ficient response to anakinra, rilonacept and canakinumab 
can be considered because they have longer half-lives 
and can be administered every week or every 8 weeks, 
respectively. Indeed, both agents have been reported to be 
efficient in AOSD.53–56
More data are available in the setting of systemic-onset 
JIA.19,20,55–58 Swart et al reviewed the literature and reported on 
140 children with systemic-onset JIA treated with anakinra.57 
Systemic symptoms resolved in 98% of the patients who had 
such symptoms. Fatigue and well-being improved in 93% of 
cases. Arthritis improved in 66% of the cases within a longer 
time (few months).
Complete disease remission was mostly observed in 
patients with systemic symptoms, less arthritis, and a shorter 
Table 2 Review of previous use of biologic agents for refractory adult-onset Still’s disease
Biologic agent Reference Cases (n) AOSD 
subtype
Complete 
remission (%)
Partial  
remission (%)
Corticosteroid 
weaning (%)
Infections 
(n)
etanercept Husni et al38 12 Articular 0 58 0 1
Infliximab Cavagna et al39 3 Articular 0 67 NR 0
Kraetsch et al40 6 Both 67 33 NR 0
Kokkinos et al41 4 Both 100 0 25 0
etanercept and 
infliximab
Fautrel et al42 20 Articular 25 55 NR 2
Anakinra Fitzgerald et al47 4 Systemic 75 25 75 1
Kalliolias et al48 4 Systemic 25 75 75 0
Kötter et al49 4 Both 100 0 NR 0
Lequerré et al35 15 Both 64 87 13 2
Laskari et al50 25 Both 84 12 48 7
Nordström et al52 12 Both 50 NR 25 0
Giampietro et al112 28 Both 43 14 NR NR
Tocilizumab Puéchal et al59 14 Articular 57 7 NR 0
Cipriani et al60 11 Both 82 18 8 1
 elkayam et al61 15 Articular 80 13 9 0
Abbreviations: AOSD, adult-onset Still’s disease; NR, not reported.
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duration of disease. Adverse events were most frequently 
pain and erythema at the injection site. More serious adverse 
events were rare (occurring in eight cases). Quartier et al 
confirmed the efficacy of anakinra in systemic-onset JIA by 
performing a multicenter, randomized, placebo-controlled 
clinical trial.58 The study included 24 patients with a 
systemic-onset JIA duration of more than 6 months and 
steroid dependency. After one month, anakinra had been 
effective in 8/12 patients (versus one in the placebo group) 
who reached the modified American College of Rheuma-
tology Pediatric 30 score. At month 2, 9/10 patients in the 
placebo group who had been switched to anakinra were also 
responders. However, during the following open-label treat-
ment period, a loss of response was observed over time and 
no patient achieved inactive disease.
Nigrovic et al reported on 46 patients who received 
anakinra as first-line treatment.19 Rapid resolution of sys-
temic symptoms was observed in more than 95% of cases, 
along with an additional preventive effect on refractory 
arthritis in almost 90% of the patients. Notably, 60% of the 
patients achieved inactive disease. Based on these results, 
Nigrovic postulated that there could be a “window of oppor-
tunity” for IL-1 blockade if given at the very beginning of 
the disease (ie, within 6 months after onset).18 In Nigrovic’s 
model, systemic-onset JIA/AOSD would have a biphasic 
pattern. The first phase, being febrile and inflammatory, 
involves innate immunity, and evolves to an afebrile phase 
with chronic destructive arthritis involving adaptive immu-
nity. This hypothesis has been somewhat reinforced by 
the results reported by Vastert et al in 2014.20 Indeed, they 
reported on a prospective series of 20 patients who received 
anakinra as first-line therapy. Eighty-five percent of the 
patients showed an American College of Rheumatology 
Pediatric 90 score response or had inactive disease within 3 
months. Overall, 75% of the patients treated with anakinra 
alone achieved inactive disease. Although it is difficult to 
evaluate to what extent children with new-onset systemic-
onset JIA enrolled in that study would have underwent 
monocyclic course (ie disease that never relapses), these 
dramatic results clearly indicate that IL-1 blockade has an 
early place in the treatment strategy. 
Tocilizumab
Tocilizumab is a humanized monoclonal antibody directed 
against the IL-6 receptor that has shown positive results in 
patients with refractory AOSD from several case series.59–62 
Results from randomized placebo-controlled trials are 
available in systemic-onset JIA but not in AOSD.63,64 
Generally, the patients responded rapidly and experienced 
a sustained clinical remission over time. Moreover, the 
effect of tocilizumab persisted for 6 months after its 
discontinuation. Tocilizumab seems to have a similar 
beneficial effect on the systemic and articular features of 
AOSD, has a marked corticosteroid-sparing effect, and 
has a good safety and tolerance profile.59–61,63 Indeed, in 
a recent retrospective series, only two cases among 34 
tocilizumab-treated patients with AOSD had to withdraw 
from treatment due to severe infections.62 Other side effects 
were mild leukopenia or neutropenia, elevation of hepatic 
enzymes, hypercholesterolemia, and headache associated 
with tocilizumab infusion.
Optimal management of AOSD
Since the management of AOSD varies widely depending on 
the various clinical presentations of the disease, the optimal 
management is discussed in the second part of this review. 
A management algorithm is provided in Figure 1.
Nonrefractory AOSD
According to the abovementioned definition, nonrefractory 
AOSD corresponds to disease patterns that can be cured by 
using first-line corticosteroids ± methotrexate. This mostly 
includes the monocyclic and polycyclic courses of the dis-
ease, when corticosteroid dependency can be overcome with 
a first-line steroid-sparing agent. NSAIDs can be used dur-
ing the diagnostic workup, in case of a monocyclic course 
of AOSD without major systemic or articular involvement 
or in case of isolated mild articular involvement. In such 
cases, the preferred NSAID is high-dose indomethacin 
(150–200 mg/day).26,65,66 
Corticosteroids should be started promptly once the 
diagnosis is confirmed. Usually, corticosteroid therapy starts 
at a dosage of 0.5–1 mg/kg/day, but an intravenous pulse 
of high-dose methylprednisolone can be used, particularly 
where there is severe visceral involvement.67,68 Higher dos-
ages seem to be more efficient in controlling the disease, 
achieving remission earlier, and decreasing the number 
of relapses.10 Fractionated daily intakes of corticosteroids 
have also provided interesting results in insufficiently con-
trolled patients.26,69 The response to corticosteroids should 
be obtained within hours or days.70 Usually, the tapering of 
corticosteroids can start after 4–6 weeks, when symptoms 
have resolved and biological parameters have returned to 
normal.
If patients show early signs of corticosteroid dependency 
or have the previously mentioned risk factors (splenomegaly, 
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low glycosylated ferritin, elevated erythrocyte sedimenta-
tion rate, or young age at AOSD onset16,25), methotrexate 
could be considered early for its steroid-sparing effect. 
Usually, methotrexate (7.5–20 mg/week) enables complete 
remission of the disease (70%) or at least a significant 
reduction of daily corticosteroid intake.29 Methotrexate 
has a similar effect on systemic and arthritic AOSD.17,29 
Blood count, renal function, and liver enzymes should be 
monitored before initiation of methotrexate and then every 
1–2 months.71 If methotrexate fails to control the disease, 
other DMARDs could be considered. However, growing 
evidence suggests using targeted biologic therapies as early 
second-line treatment. 
Refractory AOSD
It is becoming increasingly apparent that AOSD patients fall 
into two distinct subsets, ie, those presenting with systemic 
features and those presenting with prominent arthritis.10,13–15 
These findings are supported by molecular evidence, cytokine 
profiles, clinical course, and response to treatment (Figure 2). 
In AOSD, such as in systemic-onset JIA, it remains unclear 
whether the two subsets of the disease are temporally related 
(biphasic disease)18 or present since the disease onset.
Predictive factors for a prominent articular pattern 
include female sex, proximal arthritis at disease onset, 
thrombocytosis, and corticosteroid dependency, whereas 
high fever, high levels of liver enzymes, or high acute phase 
reactants are more likely to be associated with a systemic 
pattern of AOSD.72–74 Other clues to identify the systemic 
subtype of AOSD are the following: thrombocytopenia, 
RHL, and hyperferritinemia. Although the cytokine dosage 
is not performed in routine care, IL-18, interferon-γ, IL-10, 
and IL-4 are associated with systemic AOSD whereas IL-6, 
IL-17, and IL-23 are associated with arthritic AOSD.15,74,75 
This dichotomy may be of the utmost importance for the 
management of AOSD patients, as patients falling into 
one of the two categories should benefit from different 
treatments.10,13 
Confirmed AOSD
First line: Corticosteroids 
CS dependency
Add methotrexate
No/insufficient clinical response
Corticosteroids
± IVIg
± anti-IL-1
±
– – –
Anti-IL-1
(anakinra)
Anti-IL-6
(tocilizumab)
Anti-IL-6
(tocilizumab)
Anti-TNF-α
(infliximab)
Pregnancy
Refractory AOSD
Systemic AOSD Articular AOSD
– NSAIDs
▪ Pulse corticosteroids
▪ IVIg
▪ Anti-IL-1 (anakinra)
▪ Cyclophosphamide
▪ Cyclosporine A
▪ Plasma exchanges
Other situations
▪ RHL
▪ Myocarditis
▪ Disseminated coagulopathy
▪ Diffuse alveolar hemorrhage
– IVIg
Figure 1 Management algorithm for adult-onset Still’s disease.
Abbreviations: AOSD, adult-onset Still’s disease; CS, corticosteroids; IVIg, intravenous immunoglobulin; NSAIDS, nonsteroidal anti-inflammatory drugs; RHL, reactive 
hemophagocytic lymphohistiocytosis.
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Patients with systemic AOSD are more likely to be 
responders to first-line corticosteroid therapy. In the case of 
refractory systemic AOSD, IL-1 antagonists (mostly anak-
inra) should be considered first as they have proved to be 
dramatically more efficient for systemic symptoms than for 
articular features.16,17,35,76 Anakinra is used at 100 mg/day via 
subcutaneous injection. Once the disease is controlled and the 
biological parameters have returned to normal, subcutane-
ous injections can be spaced. The most commonly reported 
adverse event with anakinra has been self-limiting erythema 
at the injection site. Unlike anakinra, anti-TNF-α agents usu-
ally have a less sustained effect on systemic symptoms.
Tocilizumab should be considered as an alternative to 
IL-1 antagonists, particularly when articular signs such as 
joint erosion accompany systemic symptoms.10,13,77 Neverthe-
less, tocilizumab has been less widely used in treating AOSD 
and should actually be used only if anti-IL-1 treatments fail 
to control the disease or if relapses occur during weaning of 
anti-IL-1. Tocilizumab is given at a dosage of 5–8 mg/kg 
body weight every 2–4 weeks. Nevertheless, larger random-
ized studies are still needed to further determine the optimal 
therapeutic scheme for tocilizumab.
In patients with articular refractory AOSD, anti-TNF-α 
should be the preferred treatment.10,13,77,78 Infliximab, given 
with a therapeutic scheme similar to that used for rheuma-
toid arthritis (ie, 3–5 mg/kg at weeks 0, 2, and 6, and then 
once every 8 weeks), seems to have better efficacy than 
etanercept, but larger studies are required to compare these 
two molecules. Since available data on the efficacy of adali-
mumab in AOSD are lacking, it cannot be recommended so 
far. In the case of failure of anti-TNF-α, tocilizumab should 
be considered first as it has proven efficient for both the 
articular and systemic features of AOSD.10,13 If tocilizumab 
fails, anakinra may be tried.
Finally, it should be noted that, in an effort to standardize 
therapeutic management and evaluate comparative effec-
tiveness in an observational setting, the Childhood Arthritis 
and Rheumatology Research Alliance has developed four 
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Abbreviations: AOSD, adult-onset Still’s disease; iFN, interferon; iL, interleukin; NK, natural killer; TNF, tumor necrosis factor.
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consensus treatment plans for systemic-onset JIA.22 These 
plans include a glucocorticoid plan, a methotrexate plan, an 
anakinra plan, and a tocilizumab plan. As no guidelines are 
available for AOSD, this consensus plan should be of help 
for physicians dealing with new-onset AOSD.
Life-threatening complications  
of AOSD
Reactive hemophagocytic 
lymphohistiocytosis
RHL corresponds to an uncontrollable activation of the 
reticuloendothelial system leading to phagocytosis of 
hematopoietic cells by activated tissue macrophages. In 
AOSD, RHL has been reported to have an incidence of 
12%–17%.79–81 Evidence for occult RHL in a substantial 
proportion of patients with AOSD (up to 50%) supports the 
possibility that RHL and AOSD could represent the same 
disease within a continuum of severity.82,83 Considering all 
the underlying causes, the mortality rate for RHL ranges 
between 10% and 22%.84–86 The clinical picture and diag-
nostic criteria are presented in Table 3.81 Although RHL 
features resemble those of AOSD, differences exist and may 
help the early recognition of RHL during AOSD:83 the fever 
pattern is mostly non-remitting in RHL; there are less cen-
tral nervous system involvement and hepatosplenomegaly 
during AOSD flare-ups than during RHL; and neutrophil 
and platelet counts are elevated in AOSD whereas they are 
low in RHL. Notably, a rapid decrease in leukocyte count 
or the rapid appearance of an hypertriglyceridemia may 
alert the physician on the onset of RHL complicating previ-
ously diagnosed AOSD. Hypofibrinogenemia is also one 
of the most important clues indicating RHL, since AOSD 
patients are more likely to have hyperfibrinogenemia due 
to the underlying inflammatory state. Hyperferritinemia is 
difficult to interpret in an AOSD patient because an acute 
increase in total and glycosylated serum ferritin can indi-
cate a flare-up of AOSD or RHL. Bone marrow aspiration 
is the gold standard for diagnosis of RHL. It is not to be 
performed systematically but can be required in atypical 
cases and when there is a diagnostic dilemma. 
Treatment of RHL in AOSD patients has mostly been 
empirical and has consisted of intravenous pulsed corticoster-
oids or intravenous immunoglobulin.83 Several immunosup-
pressive drugs have also been used, including cyclosporine A, 
mycophenolate mofetil, or etoposide.83,87 More recently, sev-
eral authors have reported on the successful management of 
RHL complicating adult or pediatric Still’s disease using IL-1 
antagonists.88–91 It is possible that higher doses of anakinra are 
required to treat Still’s disease-associated RHL (ie, 100 mg/6 
hours).91 On the contrary, anti-TNF-α has proven ineffective 
or even harmful in treating RHL. Yet, several cases of RHL 
associated with etanercept have been reported in patients 
with AOSD.88,92 Finally, tocilizumab has been reported to 
be effective in the management of AOSD-related RHL, but 
these preliminary results still need to be confirmed.93
Disseminated intravascular coagulopathy
Disseminated intravascular coagulopathy (DIC) is charac-
terized by an unregulated overactivation of the coagulation 
system. Fewer than ten cases have been reported in the set-
ting of AOSD.83 However, the diagnosis can be challenging 
since the clinical picture may mimic sepsis and DIC may 
complicate AOSD-related RHL.94–96 The reported efficient 
treatments of AOSD-associated DIC include prednisolone,97 
cyclosporine A,96,98 anakinra,49 and tocilizumab.99 So far, 
since only few data are available, it is not possible to rec-
ommend one or another molecule. Nevertheless, taking into 
account the morbidity of DIC, it seems reasonable to propose 
early therapy with anti-IL-1 or anti-IL-6 to AOSD patients 
who do not respond rapidly to corticosteroids.96,98
Myocarditis
We recently described four previously unreported cases 
of AOSD-related myocarditis and reviewed 20 other cases 
from the literature (Gerfaud-Valentin et al Medicine100). 
Myocarditis was an early life-threatening complication 
of AOSD occurring within the first year after the disease 
onset and affecting younger patients, mostly males. All 
the patients were given high-dose corticosteroids (either 
intravenous pulses or 1 mg/kg body weight). Intravenous 
immunoglobulins were added in 6/24 patients, methotrexate 
Table 3 Diagnostic criteria for hemophagocytic lymphohis-
tiocytosis
Laboratory criteria
Decreased platelet count
elevated levels of aspartate aminotransferase
Decreased white blood cell count
Hypofibrinogenemia
Clinical criteria
Central nervous system dysfunction
Hemorrhages
Hepatomegaly
Histopathological criterion
evidence of macrophage hemophagocytosis in bone marrow aspirate
Notes: Positive diagnosis requires two or more laboratory criteria or two or 
more clinical and/or laboratory criteria. Bone marrow aspiration may be required in 
doubtful cases. Data from.81
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in 5/24, and anti-TNF-α in 3/24. In addition, one patient 
received cyclophosphamide and another received anakinra 
(100 mg/day). All but one had a favorable outcome, giving 
a fatality rate of about 4%. Thus, AOSD-associated myo-
carditis can be life-threatening but has a good prognosis 
when recognized early and efficiently treated. High-dose 
corticosteroids are the mainstay of treatment. Whether the 
other treatments are useful cannot be determined on the basis 
of this retrospective study, but in our experience, intrave-
nous immunoglobulin seems to be useful and methotrexate 
steroid-sparing.
Thrombotic thrombocytopenia purpura
About ten cases of AOSD-related thrombotic throm-
bocytopenic purpura (TTP) have been reported.83 The 
pathophysiologic link between TTP and AOSD remains 
unknown. The clinical sign that should alert the clinician is 
acute visual loss. Early detection of TTP is required because 
it is associated with high morbidity and mortality.101 Delayed 
treatment of TTP may lead to renal failure, brain edema, and 
death.102,103 Thrombocytopenia and unexplained microangio-
pathic hemolytic anemia are arguments for a diagnosis of 
TTP during AOSD.104 Plasma exchange is always required 
in the event of AOSD-associated TTP. Additional drugs 
have been used with success, such as corticosteroids, intra-
venous immunoglobulin, azathioprine, cyclophosphamide, or 
rituximab.101,103 Only one author has reported on successful 
treatment of AOSD-related TTP using tocilizumab, which 
seemed to be efficient in treating both TTP and the underlying 
refractory AOSD.105
Diffuse alveolar hemorrhage
Diffuse alveolar hemorrhage is a rare life-threatening 
complication of AOSD characterized by accumulation of 
erythrocytes in the lung alveolar spaces. Whether diffuse 
alveolar hemorrhage is a specific complication of AOSD 
or is coincidental remains unclear. Clinicians should think 
about diffuse alveolar hemorrhage when AOSD patients 
present with hemoptysis, cough, and dyspnea progressing 
to respiratory distress, together with falling hematocrit 
and hemorrhagic bronchoalveolar lavage fluid. Thera-
peutic options include an intravenous pulse of high-dose 
methylprednisolone (1 g/day for 5 days), plasma exchange, 
or intravenous cyclophosphamide.106,107
AOSD and pregnancy
We recently reviewed the link between AOSD and pregnancy.34 
In the subset of women without previously known AOSD, 
the disease occurred mainly during the first or second 
trimester. Due to flares, some cases were complicated 
by oligohydramnios or prematurity. No life-threatening 
complications were reported. In the second subset of 
women with known AOSD, flares were less frequent and 
more likely to occur during the second trimester and the 
postpartum period. Of note, data concerning preventive 
treatment are controversial and do not allow guidelines 
or recommendations.34,108 Treatment of AOSD flares dur-
ing pregnancy always included prednisone at a dosage of 
0.5–1 mg/kg body weight. The safety of corticosteroids has 
been established for usual dosages, but their effect at higher 
dosages remains unclear.109 In our previous article, it was 
not possible to state whether obstetric complications were 
due to the treatment or to the underlying disease.34 Thus, 
multidisciplinary expertise is required when corticosteroids 
are required. In some cases, intravenous immunoglobulins 
has been added but their effect on the outcome cannot 
be clearly determined.33,34 Although NSAIDs have been 
used, they are not recommended during pregnancy, par-
ticularly after week 24. Anakinra was used during three 
pregnancies in patients with AOSD. Both the outcome of 
the AOSD and the pregnancies were positive. The disease 
was controlled in all three cases and the children were born 
at term and healthy.110,111 Finally, close multidisciplinary 
monitoring before, during, and after pregnancy is required 
for women with AOSD.
Conclusion
Adult-onset Still’s disease is a complex disease with a 
polymorphic clinical presentation. In some cases, AOSD 
is as simple as a unique flare easily cured by NSAIDs or 
short-course corticosteroid therapy. On another hand, AOSD 
can present with stormy systemic features and lead to life-
threatening complications (such as RHL) or as a chronic 
articular disease that may be either indolent or destructive. 
Recent advances in our understanding of the pathophysiol-
ogy of AOSD and the availability of anti-cytokine-targeted 
treatments have given rise to more personalized treatments. 
In the near future, understanding of AOSD will probably 
benefit further from wide genetic analyses. Targeted biologic 
therapies seem to have a dramatic effect when given as first-
line treatment in systemic-onset JIA. Results from ongoing 
observational studies and future prospective trials may lead 
to the recommendation of earlier use of these treatments in 
AOSD. Finally, the management of AOSD will also benefit 
from the release of new targeted biotherapies, such as anti-
IL-18 or anti-IL-17. 
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